Clinuvel Pharmaceuticals Limited

DB:UR9 Stock Report

Market Cap: €299.9m

Clinuvel Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

DB:UR9 Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
06 May 25Buy€513,216JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany84,081€6.66
06 May 25Sell€715,335JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany114,173€6.71
28 Mar 25Buy€744,096JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany110,764€7.55
28 Mar 25Sell€629,583JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany93,092€7.45
12 Feb 25Buy€2,058,134JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany281,269€7.94
12 Feb 25Sell€760,247JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany106,678€7.92
03 Dec 24Buy€2,927,631JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany342,223€9.77
03 Dec 24Sell€3,395,320JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany394,134€9.73
21 Aug 24Buy€9,589JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany1,171€8.24
21 Aug 24Sell€1,180JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany144€8.19
20 Aug 24Buy€9,257JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany1,082€8.64
20 Aug 24Sell€16,272JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany1,926€8.59
08 Aug 24Buy€11,667JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany1,411€8.29
08 Aug 24Sell€6,084JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany728€8.43
06 Aug 24Buy€21,520JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany2,554€8.97
06 Aug 24Sell€19,478JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany2,274€8.92
30 Jul 24Buy€2,829JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany318€8.98
30 Jul 24Sell€3,224JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany362€9.06
26 Jul 24Buy€604,140JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany64,968€10.51
25 Jul 24Sell€389,522JPMorgan Chase & Co, Brokerage and Securities InvestmentsCompany42,518€10.48

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of UR9?
Owner TypeNumber of SharesOwnership Percentage
Public Companies152,1590.304%
Private Companies3,342,9936.68%
Individual Insiders5,195,64410.4%
Institutions11,620,20423.2%
General Public29,698,75059.4%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 39.86% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
8.59%
BNY Asset Management
4,296,471€25.8m0%0.01%
6.85%
Philippe Wolgen
3,425,222€20.5m0%no data
5.18%
Ender I , LLC
2,590,824€15.5m0%no data
4.55%
The Vanguard Group, Inc.
2,277,080€13.7m-5.07%no data
4.42%
JPMorgan Chase & Co, Brokerage and Securities Investments
2,210,281€13.3m-2.13%0.01%
1.43%
Dimensional Fund Advisors LP
715,455€4.3m0.46%no data
1.2%
Emilino Group Pty Ltd
601,447€3.6m0%no data
0.87%
Norges Bank Investment Management
437,018€2.6m0%no data
0.73%
Darren Keamy
362,890€2.2m0%no data
0.69%
Mark Badcock
346,772€2.1m0%no data
0.59%
AllianceBernstein L.P.
293,162€1.8m-8.17%no data
0.53%
JPMorgan Chase & Co, Private Banking and Investment Banking Investments
263,599€1.6m-29.8%no data
0.46%
David Trevorrow
229,600€1.4m0%no data
0.46%
BNP Paribas Arbitrage Sa, Asset Management Arm
229,044€1.4m0%no data
0.46%
Van Eck Associates Corporation
228,252€1.4m-4.08%no data
0.38%
Dennis Wright
188,812€1.1m0%no data
0.37%
David Lewis
185,000€1.1m0%no data
0.35%
Trent Redding
177,370€1.1m0%no data
0.3%
Spheria Asset Management Pty Ltd
152,159€912.5k0%0.17%
0.3%
Spheria Emerging Companies Limited
152,159€912.5k0%no data
0.3%
Rusty Hammer Pty Ltd
150,722€903.8k0%no data
0.29%
Simon Bown
146,000€875.5k0%no data
0.23%
Brenda Shanahan
116,577€699.1k0%no data
0.16%
Brenda Shanahan Charitable Foundation., Endowment Arm
80,000€479.7k0%no data
0.16%
Charles Schwab Investment Management, Inc.
78,457€470.5k-1.63%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/22 22:28
End of Day Share Price 2025/05/22 00:00
Earnings2024/12/31
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Clinuvel Pharmaceuticals Limited is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Thomas WakimBell Potter
Norbert KalliwodaDr. Kalliwoda Research
David StantonJefferies LLC